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Abstract
The dendritic cell (DC) possesses the ability to stimulate both T helper 1 (Th1) and Th2 responses
depending on activation stimuli. Although it is known that chemically or genetically modified DC
can be used therapeutically to steer immune responses towards either Th1 or Th2, cellular therapy
with ex vivo manipulated DC is clinically difficult. Here we demonstrate a novel method of
switching immune responses from Th1 to Th2 through in vivo immune modulation by
administration of siRNA. We demonstrate that siRNA targeting of the IL-12p35 gene leads to a
Th2 bias in vitro through an IL-10 dependent mechanism. In vivo administration of siRNA admixed
with the oil-based contrast agent lipiodol in the presence of antigen and adjuvant induced a
deviation in recall response to reduced production of IFN-γ and augmented IL-4 response using
e i t h e r  K L H  o r  o v a l b u m i n .  T h i s  s i m p l e  m e t h o d  o f  i n  v i v o  m o d i f i c a t i o n  o f  i m m u n e  r e s p o n s e
possesses therapeutic potential in Th1-mediated diseases such as multiple sclerosis and
autoimmune diabetes.
Introduction
It is known that the immune response can be polarized
into two broad subsets based on cytokine secretion of the
T helper cells. T helper-1 cells (Th1) responses are associ-
ated with anti-viral and anti-cancer immune reactions and
are characterized by high secretion of the cytokine IFN-γ
and IL-2 [1]. In contrast, Th2 responses are effective for
clearing parasitic infections such as schistosoma mansoni
and are identified by high secretion of IL-4 and IL-13 [2].
In various human diseases a pathological polarization of
the immune responses either to Th1 or Th2 is known to
occur. For example, autoimmune diseases such as diabe-
tes [3], multiple sclerosis [4], or arthritis [5], are associated
with overproduction of Th1 cytokines. The causative role
of these cytokines is noted by amelioration of animal
models of autoimmune disease through treatment with
inhibitors of such cytokines, such as antibodies or soluble
receptors; however, clinical utilization is often impeded
by systemic, non-desired side effects. Therefore a desired
method of treating autoimmune diseases associated with
Th1-hyperactivities would be targeting the actual initiat-
ing event that triggers such immune reactions.
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It is known that naïve CD4+ T helper cells (Th0) are pro-
grammed by the antigen presenting cell in order to
become polarized into either the Th1 or Th2 phenotype
[6]. More recent studies have demonstrated that dendritic
cells (DC) play a key role in recognizing the exogenous
pathogens, and making the decision of whether a Th1 or
Th2 response is needed [7]. For example, parasites contain
distinct chemical signatures that are recognized by special-
ized toll-like receptors (TLR) on DC, which instruct the
DC to promote the appropriate response. In the case of
schistosomiasis, the schistosomal egg antigen (SEA) is
known to bind to TLR-2 on DC, and stimulate production
of IL-13, which in turn shifts the Th0 cell into a Th2 cells
[8,9]. Conversely, Gram-negative bacteria contain
lipopolysaccaride (LPS), which activates TLR-4, leading to
production of IL-12 by the DC, which then stimulates Th1
differentiation [10]. Since it is established that Th1 immu-
nity is essential for clearance of many Gram-negative bac-
teria, it appears that the DC plays a "central cognitive" role
in guiding the immune response. Conversely, manipula-
tion of this cell type would allow us to selectively modu-
late immune responses to either Th1 or Th2. Since DC can
be pulsed with antigen, the manipulation of antigen-
pulsed DC would allow for selective alterations of immu-
nity in an antigen-specific manner. Although this has
been performed in animal models of autoimmunity [11-
15], the clinical utilization is hampered by the need for ex
vivo cellular manipulation, which is expensive and diffi-
cult.
RNA interference (RNAi) is the cellular defense mecha-
nism by which a double-stranded RNA specifically
silences mRNA transcripts with strict homology to the
double strand [16]. The silencing effect of exogenous dou-
ble-stranded RNA is very potent in that it can mediate
gene-silencing even at a concentration of 1–3 double
strands per cell [17]. In light of this potency and selectiv-
ity, the induction of RNAi in DC would allow for silencing
of genes that stimulate either Th1 or Th2. Since it is
known that inhibition of Th1 cytokines in DC results in
the stimulation of Th2 immunity and vice versa, we
hypothesize that silencing of IL-12 would result in DC
with a propensity of stimulating Th2 immune responses.
While we and others have been able to modify immuno-
logical parameters of DC through silencing IL-10 [18], IL-
12p35 [19], IL-12p40 [20], T-bet [21] and SOCS1 [22], a
method of easily inducing immune modulation in vivo is
lacking. In this study we induce an "in vivo genetic modi-
fication", presumably through DC using an immobilizing
agent (CFA), a transfection associated agent (lipidiol) and
antigen. We demonstrate inhibition of Th1 and upregula-
tion of Th2 responses using this simple immunization
protocol.
Materials and methods
Animals
Female C57/BL6 and BALB/c mice (The Jackson Laborato-
ries, Bar Harbor, ME), 5 wk of age, were kept in filter-top
cages at the Animal Care and Veterinary Services Facility,
the University of Western Ontario according to the Cana-
dian Council for Animal Care Guidelines. Mice were fed
by food and water ad libitum and allowed to settle for 2
wk before initiation of experimentations.
DC generation and siRNA transfection
At Day 0, bone marrow cells were flushed from the femurs
and tibias of C57/BL6 mice, washed and cultured in 6-
well plates (Corning, NY) at 4 × 106 cells/well in 4 ml of
complete medium (RPMI 1640 supplemented with 2 mM
L-glutamine, 100 U/ml penicillin, 100 µg of streptomy-
cin, 50 µM 2-ME, and 10% FCS (all from Life Technolo-
gies, Ontario, Canada) supplemented with recombinant
GM-CSF (10 ng/ml; PeproTech, Rocky Hill, NJ) and
recombinant mouse IL-4 (10 ng/ml; PeproTech). All cul-
tures were incubated at 37°C in 5% humidified CO2.
Non-adherent cells were removed after 48 h of culture
(Day 2) and fresh medium was added. After 7 days of cul-
ture, >90% of the cells expressed the characteristic DC-
specific marker CD11c as determined by FACS. DC were
washed and plated in 24-well plates at a concentration of
2 × 105 cells/well in 400 µl of serum-free RPMI 1640.
Transfection with GenePorter, lipiodol, or naked siRNA
was performed as described below on day 7 of culture.
siRNA synthesis and transfection
siRNA sequences were selected according to the method
previously used by us [19]. siRNA specific for IL-12p35
(AACCUGCUGAAGACCACAGAU) or mismatched
(mixed) control sequence (AACTGCCAGATGGATGGT-
GAC) were synthesized and annealed by the manufacturer
(Dharmacon, Lafayette, CO) and added at a concentra-
tion of 60pMol to DC cultures. For transfection, 3 µl of 20
µM annealed siRNA were incubated with 3 µl of GeneP-
orter (Gene Therapy Systems, San Diego, CA) or lipiodol
(Ultra-Fluide™ Laboratoire Guerbet, France) in a volume
of 100 µl of RPMI 1640 (serum free) at room temperature
for 30 min. This was then added to 400 µl of DC cell cul-
ture as described above. Mock controls were transfected
with 3 µl of GenePorter alone. For naked siRNA, addition
of the same concentration of siRNA was performed and
procedures were repeated in an identical manner with the
exception of addition of transfection reagent. After 4 h of
incubation, an equal volume of RPMI 1640 supple-
mented with 20% FCS was added to the cells. Twenty-four
hours later, transfected DC were washed and used for sub-
sequent experiments. DC activation was performed in 24-
well plates by stimulation with LPS (10 ng/ml; Sigma-
Aldrich, St. Louis, MO) plus TNF- (10 ng/ml; PeproTech)
for 24 hours.Journal of Translational Medicine 2006, 4:2 http://www.translational-medicine.com/content/4/1/2
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Flow cytometry
Phenotypic analysis of DC was performed using flow
cytometry on a FACScan (Becton Dickninson, San Jose,
CA) and analyzed using CellQuest software (BD Bio-
sciences). The cells were stained with FITC-conjugated
mAb against surface markers associated with DC matura-
tion: anti-mouse CD11c, anti-mouse CD40, anti-mouse
CD80, and anti-mouse CD86 (Cedarlane Laboratories,
Mississauga, ON). Ig of the same isotype were used as con-
trols. Annexin V and propidium iodine analysis for apop-
tosis, necrosis was performed using the Apotag kit
(Cedarlane Laboratories, Hornby Ontario, Canada).
Mixed lymphocyte reaction
C57/BL6 DC after transfection were irradiated (3,000 rad)
and seeded in triplicate at various concentrations in a flat-
bottom 96-well plate (Corning) for use as stimulator cells.
Splenic T cells from BALB/c mice were isolated by gradient
centrifugation over Ficoll-Paque (Amersham Pharmacia
Biotech, Quebec) and T cell nylon wool column purifica-
tion, and added as responders (5 × 105 cells/well). The
mixed lymphocytes were cultured at 37°C for 72 h in 200
µl of RPMI 1640 supplemented with 10% FCS, 100 U/ml
of penicillin, and 100 µg/ml of streptomycin and pulsed
with 1 µCi/well of 3H-labelled thymidine (Amersham
Pharmacia Biotech) for the last 16 h of culture. Cells were
harvested onto glass fiber filters, and the radioactivity
incorporated was quatitated using a Wallac Betaplate liq-
uid scintillation counter (Beckman, Fullerton, CA).
Results were expressed as the mean counts per min of trip-
licate cultures ± SEM. In some experiments anti-IL-10
(JES5 2A5, Pharmingen) or isotype control antibody were
added for the duration of the MLR at a concentration of 5
ug/ml.
Immunization with Ag/Lipiodol mixture
C57/BL6 mice were immunized intradermally at the inte-
rior side of both hind legs with 100 µl of KLH or ovalbu-
min (1 µg/µl) emulsified in CFA (Difco Laboratories,
Detroit, MI) in the presence or absence of 10 nMol siRNA
and 10% lipiodol. After 14 days mice were sacrificed and
T cells extracted as described above.
Proliferation assays
Proliferative recall responses to KLH and ovalbumin in
immunized mice were assessed by sacrificing C57/BL6
mice 14 days after immunization with antigen-loaded
DC. T cells were purified from suspensions of lymph
nodes using CD4+ T cell column (R&D Systems) after
washing in PBS. Purified T cells were cultured in 96 well
plates with irradiated syngeneic splenocytes in triplicate
and mixed with serial dilutions of KLH or OVA at concen-
trations ranging from 0–10 ug/ml. Following a 72-h incu-
bation, 1 µCi of [3H]thymidine (Amersham) was added to
each well for 16 h. Using an automated cell harvester, the
cells were collected onto glass microfiber filter, and the
radioactive labeling incorporation was measured by a
Wallac Betaplate liquid scintillation counter.
ELISA
The supernatants from recall response T cell cultures or
MLR were harvested and assessed for DC cytokines (IL-
12p70, IL-10) and T cell cytokines (IFN-, IL-4) by ELISA.
Cytokine-specific ELISA (Endogen, Rockford, IL) was used
for detecting cytokine concentrations in culture superna-
tants according to the manufacturer's instructions using a
Benchmark Microplate Reader (Bio-Rad, Hercules, CA).
Results
Lipiodol enhances transfection of functional siRNA into 
DC
We have previously demonstrated that transfection of DC
with siRNA specific for the p35 component of IL-12
induces potent gene specific silencing at the mRNA tran-
script level as demonstrated by RT-PCR and subsequently
reduced expression of the IL-12 p70 heterodimer as wit-
nessed by ELISA protein [19]. Furthermore, we and others
have reported that siRNA can be endocytosed into den-
dritic cells (DC) and other cell types in absence of trans-
fection reagent both in vitro and in vivo [23-25]. Since
lipiodol is a clinically used contrast agent with ability to
mediate transfection of siRNA[26] in vivo, we chose to
investigate whether lipiodol can be used to increase
uptake of siRNA in DC in using an in vitro system.
In our laboratory, the combination of 10 ng/ml of LPS
and TNF-α, respectively, (LPS/TNF) is used as a standard
Lipiodol can serve as a transfection reagent Figure 1
Lipiodol can serve as a transfection reagent. Day 7 bone mar-
row derived DC were cultured alone, or with IL-12 p35 spe-
cific siRNA delivered by optimized GenePorter 
concentration (3 µl/culture) or 3 concentrations of lipiodol 
(1,2, or 3 µl/culture). Following a 24 hour incubation cells 
were plated at 1 × 106 in 6 well culture dishes and activated 
for 24 hours with 10 ng/ml LPS and 10 ng/ml TNF-α. Super-
natant was harvested and analyzed by ELISA for IL-12 p70 
production.Journal of Translational Medicine 2006, 4:2 http://www.translational-medicine.com/content/4/1/2
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method of inducing activation of bone marrow derived
DC for production of IL-12, as well as upregulation of cos-
timulatory molecules such as CD40, CD80 and CD86
[27]. Using this stimulation system, and assessing IL-12
p70 production by ELISA, we sought to determine the
potency of mixed lipiodol with siRNA to p35 at suppress-
ing IL-12 production. We administered naked siRNA, and
siRNA in various concentrations of lipiodol to day-7 bone
marrow derived C57/BL6 DC. Activation by LPS/TNF was
performed on day 8 while culture supernatants were
assessed for IL-12 production on day 10 of culture. We
observed that siRNA transfection with GenePorter
induced a potent (>90%) inhibition of IL-12 production
and that the naked siRNA induced a smaller (>30%) inhi-
bition. Transfecting the siRNA with lipiodiol at concentra-
tion of 2 and 3 µl/well induced a significantly stronger
inhibition of IL-12 production (>75%) as compared to
naked siRNA, but not to the same extent as GenePorter
(Figure 1). Similarly to our previously published experi-
ments, administration of mismatched siRNA had no
inhibitory effect on production of IL-12 (data not shown).
Furthermore, although it has previously been reported
that lipiodol is not cytotoxic even at high concentrations
[28], we wanted to discount the possibility that lipiodol
was mediated non-specific killing of DC. Viability assays
using annexin-V and PI staining and analyzed by flow
cytometry demonstrated no increase in apoptosis or
necrosis in comparison to untreated DC (data not
Lipiodol transfected DC are immune modulatory Figure 2
Lipiodol transfected DC are immune modulatory. A. Day 7 bone marrow derived DC were cultured alone or transfected with 
mismatched siRNA, or IL-12p35-specific siRNA using 3 µl/culture lipiodol. Following a 24 hour incubation cells were plated at 
1 × 106 in 6 well culture dishes and activated for 24 hours with 10 ng/ml LPS and 10 ng/ml TNF-α. Supernatant was harvested 
and analyzed by ELISA for IL-10 production. B. C57/BL6 DC were transfected with mismatched siRNA, IL-12p35-specific 
siRNA or lipiodol alone, irradiated (3,000 rad) and seeded in triplicate at various concentrations in a flat-bottom 96-well plate. 
Splenic T cells from BALB/c mice were added as responders (5 × 105 cells/well). The mixed lymphocytes were cultured for 72 
h and proliferation was assessed by thymidine incorporation. C &D. IFN-γ and IL-4 concentrations, respectively, were assessed 
from MLR cultures at 48 hours of incubation.Journal of Translational Medicine 2006, 4:2 http://www.translational-medicine.com/content/4/1/2
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IL-10 is mediates immune modulation by IL-12 silenced DC Figure 3
IL-10 is mediates immune modulation by IL-12 silenced DC. A. MLR was performed with various concentrations of irradiated 
C57/BL6 stimulator DC transfected with siRNA to IL-12p35 or control transfected DC, and BALB/c responder T cells. 5 µl/ml 
of anti-IL-10 (JES5 2A5) antibody was added throughout the culture time. Supernatant was collected from 48-hour MLR cul-
tures and assessed for IFN-γ or IL-4 (B) by ELISA.Journal of Translational Medicine 2006, 4:2 http://www.translational-medicine.com/content/4/1/2
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Inhibition of recall response by lipiodol/siRNA vaccine Figure 4
Inhibition of recall response by lipiodol/siRNA vaccine. A. C57/BL6 mice were immunized intradermally at the interior side of 
both hind legs with 100 µl of KLH or ovalbumin (1 µg/µl) emulsified in CFA in the presence or absence of 10 nMol siRNA and 
10% lipiodol. After 14 days mice were sacrificed and T cell recall responses were assessed culturing purified CD4+ T cells with 
irradiated syngeneic splenocytes in triplicate and mixed with serial dilutions of KLH or OVA (B) at concentrations ranging from 
0–10 ug/ml. Following a 72-h incubation, proliferation was assessed by thymidine incorporation.Journal of Translational Medicine 2006, 4:2 http://www.translational-medicine.com/content/4/1/2
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shown). Overall, these data support the notion that lipi-
odol is an easy to use method of transfecting bone mar-
row derived DC in vitro DC.
Immune modulation by lipiodol/siRNA
We have previously demonstrated that DC silenced for the
IL-12p35 subunit possess an increased production of IL-
10 and are poor stimulators of MLR [19]. Using the 3 ul
concentration of lipiodol that we found most effective at
inhibiting IL-12 production in Fig 1, we verified whether
the lipiodol/siRNA treated DC possessed the same immu-
nomodulatory properties as previously reported by us.
Indeed, we observed that siRNA transfected by lipiodol
induced a specific increase in IL-10 production by LPS/
TNF stimulated DC as seen in Fig 2a. Since the specific
function of DC in vivo is stimulation of T cell responses,
we sought to determine whether the siRNA/lipiodol mix-
ture had effects on inhibition of mixed lymphocyte reac-
tion (MLR). Indeed, the siRNA specific for IL-12 p35 and
not the mismatched (mixed) control inhibited prolifera-
tion of responding T cells in a 3 day MLR with naïve BALB/
c splenocytes. Furthermore, as seen in Fig 2b the lipiodol
alone did not suppress allostimulatory ability of the DC,
indicating that the siRNA itself was specifically inducing
inhibition. When supernatants of the MLR were assayed
for the prototypic Th1 and Th2 cytokines IFN-γ and IL-4,
respectively, an inhibition of IFN-γ Fig 2c, and upregula-
tion of IL-4 Fig 2d was observed. This data is in agreement
with our previous work in which we demonstrated Th1 to
Th2 immune modulation by silencing of the IL-12 p35
subunit [19]. Furthermore, the current data supports the
use of lipiodol as a transfection reagent for induction of
immune modulation by siRNA.
Th1 > Th2 shift is associated with IL-10 production
In our previous studies we have observed that silencing IL-
12 is associated with an upregulation in IL-10 production
[19]. While IL-10 has previously been described to be a
Th2 cytokine [29], it has recently been implicated in gen-
eration of CD4+ CD25+ T regulatory cells [30] and TR1
cells [31]. We wanted to assess whether siRNA silencing
mediated immune modulation is associated with auto-
crine IL-10 production by the DC. Indeed, it is known that
immature and tolerogenic DC produce this cytokine in an
autocrine fashion [32] and that gene-silencing of IL-10 on
DC stimulates Th1 immunity and DC maturation [18].
With this in mind we added blocking anti-IL-10 antibod-
ies to siRNA treated DC during stimulation of allogeneic
BALB/c T cells in MLR. A dose-dependent inhibition in
ability to stimulate Th1 responses was seen with addition
of anti-IL-10. Specifically, the IL-12 silenced DC stimu-
lated the responding T cells to decrease production of IFN-
γ and increase production of IL-4 as depicted in Fig 3a and
3b respectively. Noteworthy is the observation that com-
plete inhibition of Th1 stimulation was not achieved by
anti-IL-10, implying that stimulation of IFN-γ and inhibi-
tion of IL-4 was not completely dependent stimulation of
IL-10 and was due to other factors such as suppression of
IL-12. Addition of isotype control antibody did not influ-
ence cytokine production or proliferation (data not
shown).
Table 1
Surface molecules (MFI)
CD80 CD86 CD40
Unactivated DC
Media Control 571.7 (± 23) 1194 (± 125) 29.5 (± 1.5)
Lipiodol Control 567.3 (± 21) 1251 (± 173) 28.6 (± 1.3)
Mixed siRNA 572.5 (± 10) 1365 (± 157) 29.7 (± 1.3)
siRNA alone 559.6 (± 33) 1201 (± 193) 30.1 (± 0.9)
siRNA + Lipiodol 577.3 (± 15) 1195 (± 103) 30.4 (± 1.3)
Post-MLR
Lipiodol Control 1962.9 (± 136) 2707.1 (± 576) 140.5 (± 35.4)
Mixed siRNA 1933.2 (± 324) 3031.6 (± 489) 170.3 (± 26.9)
siRNA alone 1905.7 (± 351) 2759.9 (± 392) 167.2 (± 46.9)
siRNA + Lipiodol 2050.8 (± 119) 3051.1 (± 335) 153.3 (± 36.7)
Post-MLR + Anti-IL10
Lipiodol Control 3529 (± 302) 4862 (± 583) 236.0 (± 47.3)
Mixed siRNA 3442 (± 247) 4777 (± 773) 242.8 (± 58.9)
siRNA alone 3723 (± 453) 4863 (± 669) 237.4 (± 43.5)
siRNA + Lipiodol 3985 (± 339) 4957 (± 501) 254.3 (± 49.3)
Surface staining for FACS analysis was performed using anti-CD11c Ab (gated DC) and anti-CD80, CD86 or CD40 Abs (MFI values). Samples 
stained with the appropriate isotype-matched control Abs were analyzed in parallel to establish the gating criterion. Results are representative of at 
least three independent experiments for each culture condition.Journal of Translational Medicine 2006, 4:2 http://www.translational-medicine.com/content/4/1/2
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While we previously demonstrated that IL-12 silenced DC
possessed similar levels of costimulatory molecules as
wild-type DC [19], we did not assess whether differences
were present after stimulation of DC during the MLR proc-
ess. This would be anticipated since activated T cells pro-
duce a variety of membrane bound (CD40L, CD134L),
and soluble factors (IFN-γ, TRANCE) that stimulate DC
maturation [33-37]. Extracting DC using magnetic acti-
vated cell sorting (MACS) after the MLR demonstrated sig-
nificant increases in the mean fluorescent intensity of
CD40, CD80 and CD86, however no difference was
observed between IL-12 silenced or non-silenced DC. As
seen in Table 1, it does not appear that IL-12 silencing
leads to Th1>Th2 due to alternation in costimulatory
molecule expression. This is particularly interesting since
it is known that IL-10 suppresses CD40, CD80, and CD86
expression on DC [38]. Indeed, addition of anti-IL-10
antibody to the MLR significantly increased expression of
all 3 costimulatory molecules Table 1. This is in agree-
ment with higher expression of CD40, CD80, and CD86
in IL-10 knockout DC during the process of MLR stimula-
tion as compared with wild-type DC [39].
Lipiodol/siRNA induces Th1>Th2 shift in vivo
Having demonstrated above that lipiodol can serve as a
transfection reagent for uptake of siRNA in DC, combined
with the fact that lipiodol is commonly used for a variety
of clinical applications [40,41], we assessed whether lipi-
odol/siRNA can be used to modulate immune responses
in vivo. Accordingly, we used the KLH and OVA recall
responses as an indicator. C57BL/6 mice were immunized
with the IL-12 siRNA/lipiodol mixture combined with
CFA and either KLH or OVA. 14 days following immuni-
zation, recall response experiments were performed using
isolated CD4 T cells from draining lymph nodes as previ-
ously performed by us [19]. Proliferative responses for
both antigens were significantly inhibited in the lipiodol/
siRNA treated animals at restimulation concentrations of
In vivo immune modulation lipiodol/siRNA vaccine Figure 5
In vivo immune modulation lipiodol/siRNA vaccine. C57/BL6 mice were immunized intradermally at the interior side of both 
hind legs with 100 µl of KLH or ovalbumin (1 µg/µl) emulsified in CFA in the presence or absence of 10 nMol siRNA and 10% 
lipiodol. After 14 days mice were sacrificed and T cell cytokine responses were assessed culturing purified CD4+ T cells with 
irradiated syngeneic splenocytes in triplicate and mixed with serial dilutions of antigen. IFN-γ in KLH (A) and ovalbumin (C) cul-
tures, and IL-4 in KLH (B) and ovalbumin (D) cultures was assessed by ELISA.Journal of Translational Medicine 2006, 4:2 http://www.translational-medicine.com/content/4/1/2
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5 and 10 ug/ml (Fig 4a and 4b). When supernatants were
harvested and analyzed by ELISA for cytokine response, a
Th1>Th2 shift was observed for both KLH and ovalbumin
as demonstrated by higher production of IFN-γ (Fig 5a
and 5c) and IL-4 (Fig 5b and 5d), respectively. In order to
assess for antigen specificity, in some experiments, mice
were immunized with siRNA/lipiodol with KLH and con-
currently injected with mixed siRNA/lipiodol and OVA.
The recall response to KLH was suppressed in terms of
proliferation and possessed a Th2 cytokine profile,
whereas the response to OVA was not immune modulated
(data not shown). Other experiments not shown included
the immunization in absence of lipiodol which did not
result in any immunomodulatory effect of siRNA. Overall,
these experiments strongly suggest that siRNA can be
administered both in vitro and in vivo for immune mod-
ulatory purposes using lipiodol as a carrier.
Discussion
Lipiodol (trade name Ultra-Fluide™) is an iodized poppy
seed oil fatty acid ethylester commonly used as contrast
media for radiography [42]. Commonly, lipiodol alone or
with chemotherapy is administered to patients with
hepatic cell carcinoma for embolization of tumor-feeding
arteries, as well as localized delivery of chemotherapy
[43]. The finding that lipiodol selectively is uptaken by
endothelial cells through pinocytosis [28], combined
with the fact that it has previously been used for siRNA
delivery in vivo [26] stimulated us to question whether
lipiodol can be used as a carrier for siRNA. We observed
that although lipiodol was not as effective as GenePorter
for in vitro transfection and gene silencing, the inhibitory
effects where several fold more potent than the adminis-
tration of naked siRNA.
We therefore continued to seek whether lipiodol transfer
of siRNA can still mediate the immune modulatory effects
previously reported by us in terms of switching Th1 to Th2
responses [24]. Although this was the case, we also
observed that the switch was dependent on IL-10 produc-
tion. This is somewhat interesting since although IL-10 is
a Th2 cytokine, secretion of IL-10 has also been demon-
strated to stimulate CD8 proliferation [44], and even to
suppress atopy [45], a manifestation of classical Th2
responses. In this study our data supports a prototypic
role of IL-10 secreted by DC in stimulation of IL-4 and
IFN-γ production. We are however aware that assessment
of other Th1/Th2 associated factors are needed to conclu-
sively demonstrate a Th2 switch was occurring. Addition-
ally, although in our hands, similar culture situations
stimulate IL-10 production primarily by DC, we can not
rule out the production of IL-10 by T cells. Future studies
involve looking at T cell transcription factors such as T-bet
and GATA-3, associated with Th1 and Th2 cells, respec-
tively [46].
While we were able to induce in vivo immune modula-
tion through administration of the lipiodol/siRNA mix-
ture, we did not demonstrate that in vivo the DC were
indeed the culprits for immune modulation. As previ-
ously stated, lipiodol in vivo is pinocytosed by endothe-
lial cells [28], and most likely by other cells such as
monocytes and macrophages. Indeed both endothelial
cells, and macrophages have been demonstrated to pos-
sess immune modulatory activity. For example, antigen
presentation by unmanipulated endothelium is known to
mediate tolerance in various situations [47,48]. Indeed we
conceived that the lipiodol itself may be inducing
immune modulation due to specific targeting of antigen
to endothelial presentation, however this was not the case
since lipiodol together with antigen, or together with anti-
gen and mixed siRNA did not mediate immune modula-
tion. However, the fact that the endothelial cells
themselves are protolerogenic may allow for synergy with
the tolerogenic siRNA administered. The involvement of
macrophages in the immune modulation witnessed is
another possibility. Indeed, macrophages have been
reported to acquire an M1/M2 phenotype similar to Th1/
Th2 [49]. Preliminary experiments have indicated refrac-
toriness to IL-12 production after LPS/TNF stimulation of
CD11c DC derived from draining lymph nodes 2–3 days
after administration of lipiodol/siRNA, however this will
be the subject of an upcoming paper.
Regardless of the cellular mechanisms involved, the abil-
ity to immune modulate through administration of a
"vaccine composition" with siRNA opens a whole world
of novel possibilities both therapeutic and experiments.
Through alleviating the need for ex vivo cellular process-
ing, simple siRNA based vaccines can be developed for a
variety of disease indications where a Th switch is desired.
In terms of clinical applicability, the addition of siRNA for
embolization of tumors would allow for induction of
immune stimulation at the site of tissue necrosis. This
would permit induction of immune responses to antigens
released during the embolization procedure. Indeed simi-
lar approach used by Adema et al has demonstrated suc-
cessful induction of immunity through tissue damage
combined with immune stimulation [50].
In conclusion, we demonstrate that siRNA can be admin-
istered through a clinically useful method, thus opening
the possibilities of genetic immune modulation without
the use of viruses or ex vivo cellular manipulation.
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